Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare)
Systemic antipsoriatic treatment options are increasing rapidly. The aim of this nationwide discrete choice experiment was to compare patients’ (n = 222) and physicians’ (n = 78) preferences for outcome and process attributes of systemic antipsoriatics using Relative Importance Scores (RIS). Both gr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2017-11-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2834
|
| _version_ | 1819003192636080128 |
|---|---|
| author | Marthe-Lisa Schaarschmidt Raphael Herr Mandy Gutknecht Katharina Wroblewska Sascha Gerdes Michael Sticherling Matthias Augustin Wiebke K. Peitsch |
| author_facet | Marthe-Lisa Schaarschmidt Raphael Herr Mandy Gutknecht Katharina Wroblewska Sascha Gerdes Michael Sticherling Matthias Augustin Wiebke K. Peitsch |
| author_sort | Marthe-Lisa Schaarschmidt |
| collection | DOAJ |
| description | Systemic antipsoriatic treatment options are increasing rapidly. The aim of this nationwide discrete choice experiment was to compare patients’ (n = 222) and physicians’ (n = 78) preferences for outcome and process attributes of systemic antipsoriatics using Relative Importance Scores (RIS). Both groups considered Psoriasis Area and Severity Index 90 (PASI 90) to be most important (RIS 21.4 and 20.8, respectively). Moreover, patients were highly concerned about mild and severe adverse events (RIS = 18.2 and 14.2), physicians about severe adverse events (RIS = 14.9) and cost (RIS = 13.8). Compared to physicians, patients worried more about mild adverse events and treatment location, but less about cost and frequency of laboratory tests. Physicians’ preferences were influenced by work experience and percentage of biological prescriptions, patients’ preferences by age, disease duration and severity. Older and less severely affected patients recruited via a patient organization focused more on safety, but less on efficacy and time until response than did patients from study centres. In conclusion, these differences in trade-offs should be integrated into a shared decision-making. |
| first_indexed | 2024-12-20T23:17:06Z |
| format | Article |
| id | doaj.art-aac332f3a1c74da8aac0952afa7e77d2 |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-12-20T23:17:06Z |
| publishDate | 2017-11-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-aac332f3a1c74da8aac0952afa7e77d22022-12-21T19:23:37ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572017-11-0198220020510.2340/00015555-28345107Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare)Marthe-Lisa Schaarschmidt0Raphael HerrMandy GutknechtKatharina WroblewskaSascha GerdesMichael SticherlingMatthias AugustinWiebke K. Peitsch Department of Dermatology, University Medical Center Mannheim, Heidelberg University, DE-68135 Mannheim, Germany. Systemic antipsoriatic treatment options are increasing rapidly. The aim of this nationwide discrete choice experiment was to compare patients’ (n = 222) and physicians’ (n = 78) preferences for outcome and process attributes of systemic antipsoriatics using Relative Importance Scores (RIS). Both groups considered Psoriasis Area and Severity Index 90 (PASI 90) to be most important (RIS 21.4 and 20.8, respectively). Moreover, patients were highly concerned about mild and severe adverse events (RIS = 18.2 and 14.2), physicians about severe adverse events (RIS = 14.9) and cost (RIS = 13.8). Compared to physicians, patients worried more about mild adverse events and treatment location, but less about cost and frequency of laboratory tests. Physicians’ preferences were influenced by work experience and percentage of biological prescriptions, patients’ preferences by age, disease duration and severity. Older and less severely affected patients recruited via a patient organization focused more on safety, but less on efficacy and time until response than did patients from study centres. In conclusion, these differences in trade-offs should be integrated into a shared decision-making. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2834 biologicalsconjointanalysisdiscretechoiceexperimentpreferencespsoriasissystemictreatment |
| spellingShingle | Marthe-Lisa Schaarschmidt Raphael Herr Mandy Gutknecht Katharina Wroblewska Sascha Gerdes Michael Sticherling Matthias Augustin Wiebke K. Peitsch Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) Acta Dermato-Venereologica biologicals conjointanalysis discretechoiceexperiment preferences psoriasis systemictreatment |
| title | Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) |
| title_full | Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) |
| title_fullStr | Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) |
| title_full_unstemmed | Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) |
| title_short | Patients’ and Physicians’ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) |
| title_sort | patients and physicians preferences for systemic psoriasis treatments a nationwide comparative discrete choice experiment psocompare |
| topic | biologicals conjointanalysis discretechoiceexperiment preferences psoriasis systemictreatment |
| url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2834
|
| work_keys_str_mv | AT marthelisaschaarschmidt patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT raphaelherr patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT mandygutknecht patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT katharinawroblewska patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT saschagerdes patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT michaelsticherling patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT matthiasaugustin patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare AT wiebkekpeitsch patientsandphysicianspreferencesforsystemicpsoriasistreatmentsanationwidecomparativediscretechoiceexperimentpsocompare |